Semax
ACTH(4-7)PGP
Russian-developed neuropeptide approved in Russia for stroke and TBI. Increases BDNF and NGF. Intranasal administration crosses blood-brain barrier effectively. Under FDA review for US Category 1 status.
Mechanism of action
Stimulates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) production. Upregulates serotonin and dopamine receptors. Increases cerebral blood flow. Inhibits enkephalin degradation. Penetrates blood-brain barrier via intranasal route within minutes.
Effects in the body
Russia uses Semax clinically after strokes and traumatic brain injuries. It amplifies the brain's own repair factors — BDNF and NGF govern neuron survival and plasticity. Intranasal administration is uniquely effective because it bypasses the blood-brain barrier entirely.
Pros & cons (from the literature)
- Clinically approved in Russia with published safety data
- Nasal administration — no injection required
- BDNF elevation without significant systemic side effects
- Studied for stroke, TBI, ADHD, anxiety, and cognitive enhancement
- Rapid onset via intranasal route within minutes
- Currently Category 2 — cannot be legally compounded in USA as of 2026
- No completed Western randomized controlled trials
- May cause anxiety or overstimulation at higher doses
- Regulatory uncertainty limits access in USA
- Long-term Western safety data not established
Protocol summary (from published research)
Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.
FDA & regulatory status
Evidence base
Multiple Russian clinical trials published. Limited Western peer-reviewed independent data. Mechanism of BDNF elevation is well-established scientifically. Considered one of the most evidence-backed cognitive peptides by international researchers.
Primary research sources
Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.
Expert perspective — Dr. Alex Tatem, Urologist
Dr. Alex Tatem is a board-certified Urologist and Men's Health Specialist who has studied peptides for 12 years. Videos featured for educational purposes. ThePeptide.expert is an independent platform.
Dr. Tatem covers Semax as a cognitive peptide — explaining its intranasal administration and neuroprotective research applications.
Common questions about Semax
What is Semax approved for?
Semax is approved in Russia for stroke recovery, TBI, and cognitive disorders. It has 40+ years of clinical use in Russia. It is not FDA approved in the United States. The FDA's PCAC voted 8-5 to recommend Semax for the 503A compounding Bulks List on July 24, 2026 — formal rulemaking still required.
How is Semax administered?
Semax is typically administered intranasally (nasal drops) in research contexts. This allows central nervous system delivery without injection. Injectable administration is also studied. Intranasal is the most practical route for independent research use.
Have a question about Semax that isn't answered here? Pro members can ask the Expert's Assistant.
Upgrade to Pro to ask →